Mineo Takei

Harasanshin Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Tadashi Kurimoto

Japan Science and Technology Agency

Takao Tanaka

Suntory Foundation for Life Sciences

Momokazu Gotoh

Chukyo Hospital

Akito Yamaguchi

Harasanshin Hospital

Yoshihisa Fukuta

Zeria Pharmaceutical (Japan)

Raita Higashino

Zeria Pharmaceutical (Japan)

Koji Yoshinaga

Zeria Pharmaceutical (Japan)

Narihito Seki

Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers

Youichi Fukuda

Kindai University

Yukio Homma

The University of Tokyo

Cooperative Institutions

Zeria Pharmaceutical (Japan)

Kyushu University

Central Research Laboratories (United Kingdom)

The University of Tokyo

Harasanshin Hospital

Nagoya University

Kyoto University

National Hospital Organization

Tohoku University

Tokyo Medical and Dental University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Properties of an arachidonic acid-induced model of peripheral arterial occlusion in rats

The Japanese Journal of Pharmacology (1997)

Yoshihisa Fukuta Youichi Fukuda Takao Tanaka Raita Higashino Mineo Takei

10.1016/s0021-5198(19)44796-3

Cite

Citations (0)

A Kampo medicine, choreito, evaluated on female lower urinary tract symptoms (LUTS) with bladder pain

Traditional & Kampo Medicine (2024)

Mineo Takei Yohei Tokita Marie Hamaguchi Manami Aishima Sachiko Ichikura

Abstract Aim Choreito (CRT) is a pharmaceutical‐grade Kampo medicine and has been widely prescribed for patients with lower urinary tract symptoms (LUTS) and cystitis in Japan. The purpose of this study was to investigate the efficacy and safety of CRT in patients with persisting bladder pain. Methods This study was an open‐label, single‐arm exploratory study (Registration No. jRCTs071190017), and CRT was administered orally for eight weeks in addition to the standard therapy. The primary end‐point was the change in Core Lower Urinary Symptoms Score (CLSS) Q9 (bladder pain) from baseline to eight weeks after treatment. The secondary end‐points were all items of CLSS, International Prostate Symptom Score (IPSS), numerical rating scale of bladder pain, uroflowmetry, residual urine volume test, bladder diary and Overall Treatment Efficacy (OTE). Results In all, 13 female LUTS patients with bladder pain were enrolled. In the primary end‐point, CLSS Q9 (bladder pain) score significantly decreased at the point of week 8. Among secondary end‐points, IPSS Q7 (nocturia) has significantly decreased at weeks 4 and 8 compared with week 0. The numerical rating scale of bladder pain has significantly decreased at week 4. The 24‐hr urine volume significantly increased at week 8. However, no statistically significant changes in other subscores were observed. In satisfaction with CRT treatment according to OTE, 53.8% of patients reported “slightly improved.” There were no adverse drug reactions from CRT. Conclusion We concluded that CRT has demonstrated therapeutic efficacy for bladder pain. CRT could be potentially a useful add‐on treatment for patients persisting with bladder pain.

Kampo

10.1002/tkm2.1437

Cite

Citations (0)

Effect of liver hydrolysate on hepatic proliferation in regenerating rat liver.

Folia Pharmacologica Japonica (1999)

Youichi Fukuda Miyuki Sawata Masataka Washizuka Raita Higashino Yoshihisa Fukuta

ウシ肝臓水解物のラット肝再生に対する作用について70%部分肝切除モデルを用いて検討した.肝臓水解物は肝切除24時間後の肝重量を用量依存的に増加させ, その効果は, 0.5g/kg, p. o. の用量から有意であった.細胞増殖の指標として, 肝オルニチンデカルボキシラーゼ (ODC) 活性およびproliferating cell nuclear antigen (PCNA) labeling indexについて検討した.肝臓水解物は肝切除4時間および24時間後の肝細胞質中の0DC活性を有意に上昇させた.また, 肝切除24時間後のPCNA labeling indexを用量依存的に上昇させ, その効果は0.5g/kgの用量から有意であった.以上の結果から, 肝臓水解物は肝再生促進作用を有すことが示唆された.

Liver Regeneration

10.1254/fpj.114.233

Cite

Citations (3)

CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells

Life Sciences (2011)

Hiroki Kato Koichi Seto Nobuyoshi Kobayashi Koji Yoshinaga Tim Meyer

Pancreatic carcinoma

10.1016/j.lfs.2011.07.019

Cite

Citations (5)

Haploinsufficiency of 8p22 may influence cancer-specific survival in prostate cancer

Cancer Genetics and Cytogenetics (2007)

Hideyasu Matsuyama Kazuo Oba Kenji Matsuda Satoru Yoshihiro Manabu Tsukamoto

Haploinsufficiency

Cosmid

Gene dosage

10.1016/j.cancergencyto.2006.11.008

Cite

Citations (5)

The development of the ICIQ‐UAB: A patient reported outcome measure for underactive bladder

Neurourology and Urodynamics (2019)

Alan Uren Nikki Cotterill Chris Harding Christopher Hillary Christopher R. Chapple

Abstract Aims To present the development of the International Consultation on Incontinence Questionnaire‐underactive bladder (ICIQ‐UAB) as the first patient reported outcome measure for the assessment of the symptoms and impact on the health‐related quality of life of UAB developed in‐line with the Food and Drug Administration Guidance for Industry. Methods Draft items were developed following 44 semi‐structured concept elicitation interviews in the UK and refined using 36 cognitive interviews. A pilot study was designed to assess the draft ICIQ‐UAB's initial psychometric properties with 54 patients recruited from European hospitals. Further concept elicitation interviews were also carried out with 11 patients in the US and 10 patients in Japan. All participants had a prior urodynamic diagnosis of detrusor underactivity. Results The cognitive interviews confirmed the initial items to be understood and interpreted as intended. Pilot testing showed that both internal consistency (Cronbach's α ≥ 0.85) and test‐retest reliability (stable patients; intraclass correlation coefficient ≥ 0.88) were high. The interviews in the US and Japan elicited symptoms and impacts that support previous findings in the UK and provided further insight into the experiences of patients in those countries. The developmental ICIQ‐UAB was refined using the evidence from all substudies. Conclusions The validity and reliability of the ICIQ‐UAB were supported in a pilot study setting and the wider cultural applicability by the additional interviews in the US and Japan. Following further validation in future clinical trials, the developmental ICIQ‐UAB is envisaged as an important tool for the monitoring of future UAB treatment strategies.

Patient-reported outcome

10.1002/nau.23947

Cite

Citations (7)

Pharmacological and clinical profile of acotiamide hydrochloride hydrate (Acofide® Tablets 100 mg), a novel therapeutic agent for functional dyspepsia (FD)

Folia Pharmacologica Japonica (2014)

Yugo Matsunaga Takao Tanaka Yoichi Saito Hiroki Kato Mineo Takei

アコチアミド塩酸塩水和物(アコファイド®錠,以下,アコチアミド)は,機能性ディスペプシア(FD)の治療薬として,ゼリア新薬工業株式会社で創製されたアセチルコリンエステラーゼ(以下,AChE)阻害薬である.FDは胃十二指腸領域から発せられる食後のもたれ感,早期満腹感,心窩部痛または心窩部灼熱感などの症状を呈するが,それらの症状の原因となりそうな器質的病変が認められない機能性消化管障害である.症状の発症要因の一つとして,FD患者において胃前庭部の運動の低下や胃排出の遅延が認められていることから,症状の改善には消化管運動を亢進させ,機能を改善させることが有用であると考えられる.アコチアミドはAChE阻害作用を有し,イヌおよびラットにおいて胃運動亢進作用を示し,さらに,アドレナリンα2受容体作動薬であるクロニジンによって惹起させた胃運動低下モデルおよび胃排出遅延モデルなどの消化管機能低下に対して改善効果を示した.臨床第II相試験において,FD患者を対象にアコチアミドの有効性を検討した結果,主要評価項目である最終調査時点の被験者の印象では本剤1回100 mg群はプラセボ群,50 mg群および300 mg群より改善率が高かった.このため,本剤1回100 mg(1日3回)を臨床推奨用量とし,臨床第III相試験で食後の膨満感,上腹部膨満感および早期満腹感の症状を有するFD患者を対象に有効性を検討した.主要評価項目である被験者の印象の改善率および3症状(食後の膨満感,上腹部膨満感および早期満腹感)消失率共に100 mg群でプラセボ群より有意に高い値を示した.よって,本剤1回100 mg 1日3回投与でのFDに対する有効性が確認された.また,本剤休薬後も改善効果が維持されることが示唆された.さらに,長期投与試験において本剤休薬後に症状の再燃が認められた場合でも,耐性を形成させることなく,服薬を再開することで再度の改善が得られると考えられた.以上のことから,アコチアミドはFD患者の食後膨満感,上腹部膨満感,早期満腹感などの諸症状に対して改善効果を示す薬剤であり,FDの治療薬として有用な薬剤になると期待される.

Hydrochloride

10.1254/fpj.143.84

Cite

Citations (2)

THE CORRELATION BETWEEN URODYNAMICS AND MORPHOLOGY IN MEN WITH BENIGN PROSTATIC HYPERPLASIA

The Japanese Journal of Urology (2002)

Hironobu Wakeda Mineo Takei Akito Yamaguchi

(Objective) We have the impression that the degree of obstruction was stronger in the patients with a middle lobe of hyperplastic nodule than in those without such a lobe in patients with benign proststic hyperplasia. In the present study, we compared the data from a pressure-flow study (PFS) and a presence of a middle lobe.(Materials and Methods) A transurethral resection for benign prostatic hyperplasia was performed in 2, 439 patients, 798 underwent PFS. The PFS findings and the presence of a middle lobe were compared with the following parameters, namely, the bladder detrusor function, the degree of obstruction, the post-voided residual volume, the maximum flow rate, the prostate volume and the resected volume.(Results) In the pressure-flow study, the rate of the normal bladder detrusor function was higher in the patients with a middle lobe than in those without such a lobe (71.9 versus 53.3%). The degree of obstruction was also stronger in the patients with a middle lobe than in those without in the patients with a normal bladder detrusor function (89.0 versus 79.4%). Then in the patients with a middle lobe, the quantity of the post-voided residual volume was greater, however, the maximum flow rate was lower.(Conclusion) Most patients with a middle lobe demonstrate an improved voiding ability after underwent a transurethral resection.

Morphology

10.5980/jpnjurol1989.93.435

Cite

Citations (0)

[Clinical experience of sildenafil citrate in our hospital].

PubMed (2002)

Mineo Takei

Source

Cite

Citations (0)

101 CHANGES IN CONTENTS OF ZINC, COPPER AND IRON IN ANIMAL TISSUES AFTER REPEATED ORAL ADMINISTRATION OF Z-103

The Journal of Toxicological Sciences (1992)

Itaru Yamaguchi Hiroko Masubuchi Keizo Shibata Mineo Takei Yukinori Mera

Source

Cite

Citations (0)